James Healy - Insider Trading Tracker

Aclaris Therapeutics, Inc.

US ˙ NasdaqGS ˙ US00461U1051

Introduction

This page provides a comprehensive analysis of the known insider trading history of James Healy. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate James Healy has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
US:YMAB / Y-mAbs Therapeutics, Inc.	Director	56,683
US:NTRA / Natera, Inc.	Director	46,260
	Director	26,497
	Director	40,851
US:KRTX / Karuna Therapeutics, Inc.	Director	0
US:AVBP / ArriVent BioPharma, Inc.	Director	1,696,752
US:CINC / CinCor Pharma Inc	Director, 10% Owner	0
US:VERA / Vera Therapeutics, Inc.	10% Owner	3,467,156
US:BOLT / Bolt Biotherapeutics, Inc.	Director	25,000
US:CHRS / Coherus Oncology, Inc.	Director	27,000
US:AVTE / Aerovate Therapeutics, Inc.	10% Owner	0
US:CMPI / Checkmate Pharmaceuticals Inc	10% Owner	0
US:INZY / Inozyme Pharma, Inc.	10% Owner	0
US:AKUS / Akouos Inc	10% Owner	0
US:ITRM / Iterum Therapeutics plc	10% Owner	1,226,514
US:NXTC / NextCure, Inc.	10% Owner	2,671,856
US:GRTX / Galera Therapeutics, Inc.	10% Owner	0
US:ETTX / Entasis Therapeutics Holdings Inc	10% Owner	0
	10% Owner	0
US:EDGE / EA Series Trust - MRBL Enhanced Equity ETF	Director	15,000
US:MRNS / Marinus Pharmaceuticals, Inc.	10% Owner	15,470
US:AMRN / Amarin Corporation plc - Depositary Receipt (Common Stock)	Director	20,548
US:ACRS / Aclaris Therapeutics, Inc.	10% Owner	0
US:MIRN / Mirna Therapeutics, Inc.	10% Owner	2,974,811
US:LIFE / aTyr Pharma, Inc.	10% Owner	0
US:HPTX / Hyperion Therapeutics Inc	Director, 10% Owner	0
US:HSGX / Histogenics Corporation	10% Owner	0
US:ITMN /	Director	0
US:ALIM / Alimera Sciences, Inc.	10% Owner	40,020
US:AERI / Aerie Pharmaceuticals Inc	10% Owner	0
US:VSAR / Versartis, Inc..	10% Owner	0
US:OCRX / Ocera Therapeutics, Inc.	10% Owner	9,364
US:ANTH / Anthera Pharmaceuticals, Inc.	Director	100,000
US:KBIO / KaloBios Pharmaceuticals, Inc.	Director	15,000
US:DRTX / Durata Therapeutics Inc	Director, 10% Owner	0
US:TSRX / Trius Therapeutics Inc	10% Owner	144,622
US:699CVR015 / MEDIPACIFIC INC CVR	Director, 10% Owner	20,000

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by James Healy. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ACRS / Aclaris Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ACRS / Aclaris Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2015-10-13	ACRS	Sofinnova Venture Partners VIII, L.P.	409,090	11.0000	409,090	11.0000	4,499,990	70	29.28	7,478,165	166.18